PGEN earnings date and last-quarter result: last quarter beat, P/E -4.15. Updated 2026-07-23.
Precigen (PGEN) Research Hub
Precigen (PGEN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 6.04 USD (-2.42%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.15, market cap 1.58B. This hub links to the full technical, earnings and options research available for PGEN.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 6.04 USD (-2.42%) |
| 52-week range | 4.43 USD – 8.98 USD |
| Trend regime | Range |
| 14-day RSI | 24.3 (Oversold) |
| Trailing P/E | -4.15 |
| Market cap | 1.58B |
| Dividend yield | 0.00% |
Available research for PGEN
Covered Call on PGEN: how it works, illustrative setup around the real 6.04 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PGEN: how it works, illustrative setup around the real 6.04 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PGEN: how it works, illustrative setup around the real 6.04 USD price, max profit/loss, breakeven and when to use it. Educational.
PGEN technical analysis: range, last 6.04 USD, RSI 24.3, 52w range 4.43 USD–8.98 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is PGEN in?
Precigen (PGEN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PGEN in an uptrend or downtrend?
As of 2026-10-26, PGEN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PGEN's trailing P/E ratio?
PGEN's trailing P/E is -4.15, with a market cap of 1.58B. See the earnings research page for full valuation detail.